Fulgent Genetics, Inc. (FLGT) Misses Q2 EPS by 26c

Fulgent Genetics, Inc. (NASDAQ: FLGT) reported Q2 EPS of $2.55, $0.26 worse than the analyst estimate of $2.81. Revenue for the quarter came in at $153.6 million versus the consensus estimate of $197.34 million.

GUIDANCE:

Fulgent Genetics, Inc. sees FY2021 EPS of $12.50, versus the consensus of $12.57. Fulgent Genetics, Inc. sees FY2021 revenue of $800 million, versus the consensus of $829 million.

For earnings history and earnings-related data on Fulgent Genetics, Inc. (FLGT) click here.

You May Also Be Interested In

• Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
• SpaceX receives Baa1 rating from Moody's with stable outlook
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance